These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15095212)

  • 1. Iron storage indices: novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy.
    Teehan GS; Bahdouch D; Ruthazer R; Balakrishnan VS; Snydman DR; Jaber BL
    Clin Infect Dis; 2004 Apr; 38(8):1090-4. PubMed ID: 15095212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron storage indices and risk of bacterial infections in hemodialysis patients.
    Teehan GS; Ruthazer R; Balakrishnan VS; Snydman D; Jaber BL
    Hemodial Int; 2004 Jul; 8(3):226-32. PubMed ID: 19379422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intravenous ascorbic acid medication on serum levels of soluble transferrin receptor in hemodialysis patients.
    Tarng DC; Hung SC; Huang TP
    J Am Soc Nephrol; 2004 Sep; 15(9):2486-93. PubMed ID: 15339999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of infectious complications between incident hemodialysis and peritoneal dialysis patients.
    Aslam N; Bernardini J; Fried L; Burr R; Piraino B
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1226-33. PubMed ID: 17699352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
    Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
    Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of risk factors for catheter-related bacteremia in 2000 permanent dual catheters for hemodialysis.
    Lemaire X; Morena M; Leray-Moragués H; Henriet-Viprey D; Chenine L; Defez-Fougeron C; Canaud B
    Blood Purif; 2009; 28(1):21-8. PubMed ID: 19325236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is systemic heparin a risk factor for catheter-related sepsis in dialysis patients? An evaluation of various biofilm and traditional risk factors.
    Diskin CJ; Stokes TJ; Dansby LM; Radcliff L; Carter TB
    Nephron Clin Pract; 2007; 107(4):c128-32. PubMed ID: 17957123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients.
    Fusaro M; Munaretto G; Spinello M; Rebeschini M; Amici G; Gallieni M; Piccoli A
    J Nephrol; 2005; 18(1):72-9. PubMed ID: 15772926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent associations between iron and mortality in hemodialysis patients.
    Kalantar-Zadeh K; Regidor DL; McAllister CJ; Michael B; Warnock DG
    J Am Soc Nephrol; 2005 Oct; 16(10):3070-80. PubMed ID: 16033854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous iron administration during the maintenance period in erythropoietin-treated hemodialysis patients: a simple and effective method.
    Nurnuansuwan S; Leelahavanichkul A; Pansin P; Eiam-Ong S
    J Med Assoc Thai; 2005 Sep; 88 Suppl 4():S184-8. PubMed ID: 16623026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous iron supplementation in children on hemodialysis.
    Leijn E; Monnens LA; Cornelissen EA
    J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of intravenous iron administration frequency on AOPP and inflammatory biomarkers in chronic hemodialysis patients: a pilot study.
    Anraku M; Kitamura K; Shintomo R; Takeuchi K; Ikeda H; Nagano J; Ko T; Mera K; Tomita K; Otagiri M
    Clin Biochem; 2008 Oct; 41(14-15):1168-74. PubMed ID: 18692036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferritin iron content in haemodialysis patients: comparison with septic and hemochromatosis patients.
    Spada PL; Rossi C; Alimonti A; Bocca B; Cozza V; Ricerca BM; Bocci MG; Vulpio C; De Sole P
    Clin Biochem; 2008 Aug; 41(12):997-1001. PubMed ID: 18541151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
    Li H; Wang SX
    Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum non-transferrin bound iron in hemodialysis patients not receiving intravenous iron.
    Prakash M; Upadhya S; Prabhu R
    Clin Chim Acta; 2005 Oct; 360(1-2):194-8. PubMed ID: 15979061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial.
    Zacharski LR; Chow BK; Howes PS; Shamayeva G; Baron JA; Dalman RL; Malenka DJ; Ozaki CK; Lavori PW
    J Natl Cancer Inst; 2008 Jul; 100(14):996-1002. PubMed ID: 18612130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.